Highest-materiality recent filing
Citius Pharma gets Nasdaq bid-price compliance extension to Feb 8, 2027
Nasdaq granted extension to Feb 8, 2027 to regain compliance with $1.00 bid price rule.
Citius Pharma Q3 FY26: LYMPHIR revenue $1.5M, net loss $8.9M, cash $17M
Q3 FY26 revenue $1.5M from LYMPHIR (vs $0 prior year); nine-month revenue $7.1M.
Citius Oncology: new institutional accounts ordering LYMPHIR up 78% QoQ
New institutions ordering LYMPHIR increased 78% in Q2 2026 vs. prior quarter; total vial orders up 31%.
Citius Oncology reports Phase 1 combo data: 24% ORR, 33% in endometrial cancer; Phase 2 planned
Phase 1 trial of LYMPHIR + pembrolizumab in 25 heavily pre-treated gynecologic cancer patients showed 24% ORR (5 partial responses); median duration of response not reached.
Citius Pharma Q2 2026: $5.6M H1 LYMPHIR revenue, 80% gross margins; raises $36.5M at Citius Oncology
Net product revenue $1.7M in Q2 (launch quarter); $5.6M in H1 2026 vs. zero a year ago.
Citius Pharma subsidiary amends $3.8M note, adds conversion at $0.90, subordinates to senior debt
Third Amendment to Promissory Note dated May 4, 2026, between Citius Oncology and Citius Pharmaceuticals.
Citius Oncology ships first international order of LYMPHIR to Europe
First international shipment of LYMPHIR (denileukin diftitox-cxdl) to Europe through a regional distribution partner.
Citius Pharma raises $5M via registered direct offering and private placement
Sold 5,076,143 shares/pre-funded warrants at $0.985 each; raised ~$5M gross, $4.5M net.
Citius shareholders elect seven directors, ratify auditor at 2026 annual meeting
All seven director nominees elected: Mazur, Holubiak, Dutia, Holuka, McGrath, Smith, Webb.
83% of target accounts have added or are actively progressing LYMPHIR through formulary review.
Phase 1 trial of LYMPHIR plus KEYTRUDA in 25 evaluable patients with relapsed/refractory gynecologic cancers showed 24% objective response rate and 48% clinical benefit rate.
Citius subsidiary reports Phase 1 data: LYMPHIR + CAR-T shows 86% ORR, 57% CR in high-risk DLBCL
ORR 86% at 1 month (57% CR, 29% PR) in 14 patients with relapsed/refractory DLBCL.
Citius Pharma posts first revenue of $3.9M from LYMPHIR launch; Nasdaq warns of bid price deficiency
Q1 FY2026 revenue $3.9M from initial LYMPHIR sales; net loss $8.2M ($0.41 loss per share).
Citius Pharma reports FY2025 net loss $39.7M; launches LYMPHIR in December 2025
Net loss $39.7M ($3.38/share) vs $40.2M ($5.97/share) prior year; no revenue.
Citius Oncology launches LYMPHIR for CTCL; first marketed product
LYMPHIR (denileukin diftitox-cxdl) now commercially available in U.S. for relapsed/refractory Stage I–III CTCL after prior systemic therapy.
LYMPHIR (denileukin diftitox-cxdl) FDA approved for CTCL; commercial launch planned Q4 2025.
Citius Pharmaceuticals raises $6.0M in registered direct offering for LYMPHIR launch
Gross proceeds ~$6.0M; net ~$5.5M after placement agent fees and expenses.
Citius Pharma Q3 fiscal 2025 net loss narrows to $9.2M; LYMPHIR launch on track for Q4
Net loss of $9.2M ($0.80 per share) vs $10.6M ($1.57 per share) in the prior-year quarter.
Citius regains compliance with Nasdaq minimum bid price requirement
Nasdaq confirmed compliance with Listing Rule 5550(a)(2) after 10 consecutive trading days with bid price at $1.00 or greater.
Gross proceeds of $6M from sale of 4.92M shares/pre-funded warrants at $1.22 per share.
Citius Pharmaceuticals increases authorized shares 10x, redeems Series A Preferred for $100
Authorized shares increased from 26M to 260M; common shares from 16M to 250M.
Citius Pharma issues $1M unsecured note at 15% interest; CEO personally guarantees
$1M principal unsecured promissory note issued to Pagoda Resources on June 2, 2025.
Citius Pharma receives Nasdaq delisting notice for bid price non-compliance
Received Nasdaq letter on May 29, 2025 for failing minimum $1 bid price for 33 consecutive business days.
Citius Pharma Q2 net loss $11.5M; cash only $26K; needs capital beyond May 2025
Net loss of $11.5M ($1.27 per share) for Q2 fiscal 2025 vs $8.5M a year ago.
Citius issues CEO super-voting stock to push 16M-to-250M share increase; quorum cut to 1/3
One share of Series A Preferred sold to CEO Leonard Mazur for $100 with 1B votes, valid only on proposed authorized share increase from 16M to 250M common shares.
Citius Oncology amends license agreement with Eisai, defers $8.2M in LYMPHIR payments to 2025
Total obligations owed to Eisai: $8,233,209.77 including $5.9M milestone and $2.33M development/inventory costs.
Citius Pharma raises $2M in registered direct offering; proceeds for LYMPHIR launch
Offering of 465,000 shares at $1.15 and 1,274,131 pre-funded warrants at $1.1499.
Citius shareholders defeat share-increase proposal, elect all director nominees
Proposal to raise authorized shares from 26M to 260M failed with 3,222,490 for vs. 1,934,414 against.
Citius Pharma Q1 2025 net loss $10.3M; prepares LYMPHIR launch H1 2025
Net loss of $10.3M ($1.30 per share) vs. $9.2M ($1.45) in Q1 2024; cash $1.1M as of Dec 31, 2024.
Citius Pharma receives permanent J-code J9161 for LYMPHIR, effective April 1, 2025
CMS assigned permanent HCPCS J-code J9161 to LYMPHIR (denileukin diftitox-cxdl) for CTCL.
Citius Pharma raises ~$3M in registered direct offering of stock and warrants
Offering of 743,496 shares plus warrants for 743,496 shares at combined price of $4.035 per unit.
Citius Pharma reports LYMPHIR launch prep progress; targeting H1 2025 commercial launch
LYMPHIR approved Aug 2024 for relapsed/refractory CTCL; commercial launch targeted H1 2025.
Citius Pharma reports FY 2024 net loss of $39.4M; FDA approval of LYMPHIR highlights
Net loss $39.4M ($5.97/share) for FY ended Sep 30, 2024 vs $32.5M ($5.57) prior year.
Citius Pharmaceuticals regains Nasdaq compliance on bid price rule
Received Nasdaq notice on Dec 18, 2024 confirming compliance with Listing Rule 5550(a)(2).
Citius Pharmaceuticals effects 1-for-25 reverse stock split to regain Nasdaq bid price compliance
Reverse split at 1-for-25 ratio effective Nov 25, 2024; split-adjusted trading begins Nov 26.
Citius Pharmaceuticals Reports Productive FDA Type C Meeting for Mino-Lok Phase 3 Program
Citius Pharma held a constructive in-person Type C meeting with the FDA on November 25, 2024, regarding its Phase 3 Mino-Lok trial for catheter-related bloodstream infections.
Citius Pharma raises $3M in registered direct offering of 12M shares and 12M warrants
Offering consists of 12M common shares and warrants for 12M shares at combined $0.25; gross proceeds $3.0M.
Nasdaq panel grants Citius Pharma extension to regain bid price compliance by Dec 3, 2024
Company received bid price deficiency notice on Sep 12, 2023, extended to Sep 9, 2024.
Citius reports 27% ORR in Phase I trial of pembrolizumab + LYMPHIR for recurrent solid tumors
27% objective response rate (4/15) and 33% clinical benefit rate; median PFS 57 weeks for patients with clinical benefit.
Citius extends employment agreement with EVP Holubiak and insider warrants to 2025
Myron Holubiak's employment term extended by one year to Oct 31, 2025; all other terms unchanged.
Citius Pharma obtains partial deferral of milestone payment to Dr. Reddy's under LYMPHIR deal
Dr. Reddy's agreed to partial deferral without penalty of a milestone payment due Sep 9, 2024.
Citius Pharma receives Nasdaq delisting determination for bid price non-compliance; plans hearing
Received delisting determination on Sept 10, 2024 after failing to regain $1.00 bid price compliance by extended deadline of Sept 9, 2024.
LYMPHIR added to NCCN Guidelines for CTCL treatment
NCCN Category 2A recommendation supports LYMPHIR as option for relapsed/refractory CTCL after at least one prior systemic therapy.
Citius Pharma completes SPAC merger, forms Citius Oncology; holds ~90% of new public company
Merger closed Aug 12, 2024; Citius Oncology expected to trade on Nasdaq as CTOR on Aug 13.
Citius Pharma Q3 net loss $10.6M; FDA approves LYMPHIR, oncology spin-off begins trading
FDA approved LYMPHIR (denileukin diftitox-cxdl) for cutaneous T-cell lymphoma on Aug 12, 2024.
Citius Pharma receives FDA approval for LYMPHIR (denileukin diftitox-cxdl) in r/r CTCL
Phase 3 study showed 36.2% ORR, 8.7% complete response, median time to response 1.41 months.
Citius Pharma: Mino-Lok Phase 3 trial meets primary endpoint (p=0.0006) in CLABSI/CRBSI
Primary endpoint: time to catheter failure significantly delayed for Mino-Lok vs control (p=0.0006); hazard ratio 0.53.
Citius Pharma Q2 net loss $8.5M; LYMPHIR PDUFA Aug 13, Mino-Lok data due Q2
Cash $12.6M at Mar 31; $15M April offering extends runway through Dec 2024.
Citius Pharma raises ~$15M in registered direct offering of common stock and warrants
Sold 21.43M shares and warrants to buy 21.43M shares at $0.70/combined unit.
Citius extends CEO/EVP warrants to April 5, 2025; exercise would yield $2.3M
Board approved one-year extension for 1,294,498 Investor Warrants held by CEO Leonard Mazur and EVP Myron Holubiak, exercise price $1.42 each.
Chief Financial Officer Jaime Bartushak will assume additional responsibilities as Chief Business Officer.
the Board appointed Myron Holubiak, the current Chief Executive Officer, to the newly created position of Executive Vice Chairman
Leonard Mazur, Citius co-founder and Executive Chairman, has been named as Chief Executive Officer and Chairman.
Max materiality 0.95 · Median 0.65 · Most common event other_material